InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China


Beijing, June 22, 2022 - InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in clinical trial of the Company’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 in China.

ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.

SHP2 is involved in mediating MAPK signaling pathway and immune checkpoint pathway for the regulation of cellular proliferation and survival. Preclinical studies have shown that ICP-189 has excellent selectivity over other phosphatases and demonstrated significant anti-tumor effects in various xenograft models.

Dr. Jasmine Cui, Co-Founder, Chairwoman and CEO of InnoCare, said, “ICP-189 has entered into clinical stage in China and the U.S.  SHP2 inhibitor has high potential for targeting a variety of solid tumors. We will push forward the clinical development of ICP-189 to provide treatment options for patients in China and around the world.”

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.